In The News

Renal cell carcinoma (RCC) trials conducted in the past 10 years used exclusion criteria deemed potentially excessive by the Friends of Cancer Research (FCR) and

After skin cancer, breast cancer is the most common cancer among women in the U.S. Although deaths from the disease have been declining over the years, thanks

The US Food & Drug Administration’s vaccine review operations are still not close to returning to pre-pandemic levels of operations, Center for Biologics Evaluation &

Lab results inform the majority of healthcare decisions, which is why patients relying on these tests need assurance that diagnostic outcomes are accurate. At the

Circulating tumor DNA (ctDNA) is associated with outcomes in patients with non–small cell lung cancer (NSCLC) treated with an immune checkpoint inhibitor (ICI), according to

Improving diversity in cancer clinical trial enrollment has become an increased priority among oncology researchers. However, strict exclusion and inclusion criteria in these trials have

Background: The FDA’s recent work on biomarker development and qualification A biomarker, according to the FDA, is “a defined characteristic that is measured as an indicator of

INSTEAD OF STARTING HER SOPHOMORE YEAR of high school in fall 2013, Lauren Telesz spent most of the term in Yale New Haven Children’s Hospital in

For results from cancer clinical trials to be more generalizable to the real world, there needs to be some loosening of exclusion criteria, say researchers.

In the increasing controversy surrounding FDA’s accelerated approval pathway, it’s far too easy to overlook why this pathway exists in the first place — to define a